Find a Clinical Trial

Print this page
ProtocolTrial Name and Objective

NCI/CTEP #9681: A Phase I Study of Cabozantinib plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors

Primary Objective: Determine the dose limiting toxicity (DLT) and recommended Phase II dose (RP2D) of the combination of cabozantinib and nivolumab and separately the combination of cabozantinib, nivolumab and ipilimumab in patients with solid tumors